根據最新的財務報表(Form-10K),Novelstem International Corp 的總資產為 $0,淨isProfitable}為 $0
NSTM 的關鍵財務比率是什麼?
Novelstem International Corp 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Novelstem International Corp 的收入按細分市場或地理位置如何劃分?
Novelstem International Corp 最大收入來源為 Tires,在最近的收益報告中收入為 13,744,000,000。就地區而言,Europe 是 Novelstem International Corp 的主要市場,收入為 6,869,000,000。
Novelstem International Corp 是否盈利?
無,根據最新的財務報表,Novelstem International Corp 的淨損失為 $0
Novelstem International Corp 有負債嗎?
無,Novelstem International Corp 的負債為 0
Novelstem International Corp 的流通股有多少?
Novelstem International Corp 的總流通股為 0
關鍵數據
前收市價
$0.009
開盤價
$0.013
當日範圍
$0.013 - $0.013
52週區間
-
交易量
--
平均成交量
--
股息收益率
--
每股盈餘 (TTM)
--
市值
--
什麼是 NSTM?
NovelStem International Corp. develops novel diagnostic technology that can predict patients resistance to chemotherapy allowing for cancer treatments and the potential to reduce resistance to chemotherapy. The company is headquartered in Boca Raton, Florida. The firm's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.